View : 322 Download: 65
A multicenter, open-label study for efficacy and safety evaluation of anagrelide in patients with treatment-naive, high-risk essential thrombocythemia as a primary treatment
- Title
- A multicenter, open-label study for efficacy and safety evaluation of anagrelide in patients with treatment-naive, high-risk essential thrombocythemia as a primary treatment
- Authors
- Byun, Ja Min; Kim, Ho Young; Nam, Seung-Hyun; Shin, Ho-Jin; Song, Seulki; Park, Jinny; Han, Sang Hoon; Park, Yong; Yuh, Young Jin; Mun, Yeung-Chul; Do, Young Rok; Sohn, Sang Kyun; Bae, Sung Hwa; Shin, Dong-Yeop; Yoon, Sung-Soo
- Ewha Authors
- 문영철
- SCOPUS Author ID
- 문영철
- Issue Date
- 2022
- Journal Title
- FRONTIERS IN ONCOLOGY
- ISSN
- 2234-943X
- Citation
- FRONTIERS IN ONCOLOGY vol. 12
- Keywords
- essential thrombocythemia; high risk; Anagrelide; phase IV clinical trial; myeloproliferative neoplasms
- Publisher
- FRONTIERS MEDIA SA
- Indexed
- SCIE; SCOPUS
- Document Type
- Article
- Abstract
- As the discussion of first-line anagrelide treatment is ongoing, we aimed to prospectively examine the efficacy and safety of anagrelide in cytoreduction therapy-naive high risk essential thrombocythemia (ET) patients in Korea. Seventy patients from 12 centers were treated with anagrelide monotherapy for up to 8 weeks, followed up until 24 months. At week 8, 50.0% of the patients were able to achieve platelet < 600 x 10(9)/L, and by 12 months, 55/70 (78.6%) patients stayed on anagrelide, and 40.0% patients showed platelet normalization. 14 patients required additional hydroxyurea (HU) for cytoreduction. The median daily dose of needed HU was 500mg (range 250mg - 1500mg). The efficacy was independent of the somatic mutation status. There were 4 thromboembolic events and 7 bleeding events during the follow-up period. The most common adverse events associated with anagrelide use were headache, followed by palpitation/chest discomfort, edema and generalized weakness/fatigue. 7 patients wished to discontinue anagrelide treatment due to adverse events (3 due to headache; 2 due to edema; 1 due to palpitation and 1 due to skin eruption). All in all, first-line anagrelide treatment showed a favorable response with tolerable safety profiles regardless of somatic mutation status.
- DOI
- 10.3389/fonc.2022.989984
- Appears in Collections:
- 의과대학 > 의학과 > Journal papers
- Files in This Item:
-
fonc-12-989984.pdf(958.9 kB)
Download
- Export
- RIS (EndNote)
- XLS (Excel)
- XML